Hindustan Laboratories IPO

Hindustan Laboratories IPO is a book-built issue of 1.41 crore equity shares, comprising a fresh issue of up to 50 lakh equity shares and an offer for sale of up to 91 lakh equity shares.

Choice Capital Advisors Private Limited is the book-running lead manager to the issue, and MUFG Intime India Private Limited is the registrar. For detailed information on the company's financials, business operations, and associated risks, investors are advised to refer to the Hindustan Laboratories IPO DRHP.

About Hindustan Laboratories Limited

Hindustan Laboratories Limited is a pharmaceutical manufacturing company primarily engaged in developing, manufacturing, and marketing a broad range of generic pharmaceutical formulations. The company largely operates under a business-to-government (B2G) model, supplying medicines to various Central and State Government healthcare programmes, institutions, and public procurement agencies across India.

The company manufactures and markets pharmaceutical products across multiple therapeutic categories and dosage forms. Its product portfolio has expanded significantly over the years, growing from 661 products in FY23 to 948 products as of September 30, 2025. This broad product offering enables the company to cater to diverse healthcare requirements and participate in a wide range of government procurement tenders.

Hindustan Laboratories operates a manufacturing facility located in Palghar, Maharashtra, which holds various quality certifications, including ISO 9001:2015, WHO-GMP, and GLP accreditations. The company has also been expanding its manufacturing capabilities through the commissioning of an additional facility aimed at increasing production capacity and supporting future growth.

The company has established a strong geographical presence, supplying pharmaceutical products across 27 States and Union Territories during FY25 and H1 FY26. Its long-standing relationships with government customers, extensive product approvals, and participation in public healthcare programmes have helped strengthen its position within the domestic pharmaceutical supply chain.

Hindustan Laboratories' growth strategy focuses on expanding its product portfolio, increasing manufacturing capacity, strengthening its presence across government procurement networks, improving operational efficiencies, and leveraging its established market position to capture growing demand for affordable healthcare solutions in India.

Industry Outlook

• India's pharmaceutical industry is one of the largest globally and continues to benefit from rising healthcare expenditure, increasing government focus on public healthcare programmes, and growing demand for affordable generic medicines.
• Government procurement remains a significant segment of the pharmaceutical market, supported by central and state healthcare schemes that aim to improve access to medicines across urban and rural regions.
• Increasing public healthcare investments, expansion of health infrastructure, and growing emphasis on affordable treatment are expected to drive higher demand for generic pharmaceutical products over the coming years.
• The generic drug segment continues to benefit from cost-conscious healthcare policies, growing patient awareness, and initiatives that encourage the use of quality-assured, low-cost medicines.
• Pharmaceutical manufacturers with diversified product portfolios and regulatory-compliant manufacturing facilities are well positioned to benefit from increasing institutional demand and tender-based procurement programmes.
• Expansion of healthcare services in Tier II, Tier III, and rural markets is creating additional opportunities for pharmaceutical suppliers servicing government healthcare networks.
• Companies with established government relationships, broad product registrations, and scalable manufacturing capabilities are expected to remain competitive as public healthcare spending continues to increase.

Hindustan Laboratories IPO Objectives

The company proposes to utilise the net proceeds from the IPO for the following objectives:

• Funding the company's working capital requirements to support its growing operations and business expansion.
• Strengthening operational capabilities by ensuring adequate liquidity for procurement, production, and supply chain activities.
• Supporting increased business volumes as the company continues to participate in government procurement programmes across India.
• Enhancing the company's ability to manage inventory requirements and fulfil large-scale institutional orders efficiently.
• Maintaining financial flexibility to support future growth initiatives and operational requirements.
• Improving overall working capital efficiency and supporting sustained business expansion.
• Meeting general corporate purposes in accordance with applicable regulations.

Financial Performance of Hindustan Laboratories Limited

Hindustan Laboratories Limited Peer Details Comparison